Disc Medicine, Inc 10-Q for FY2026 Q3
Disc Medicine, Inc. (IRON)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
Disc Medicine, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Disc Medicine reported positive APOLLO Phase 3 results for bitopertin and plans an NDA resubmission by the end of 2026. Cash, cash equivalents and marketable securities totaled $682.8 million at September 30, 2026, funding is expected into 2030. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $59.54M
- compared with a net loss of $62.32M a year earlier
- Diluted EPS
- -$1.53
- compared with -$1.77 a year earlier